Funding for this research was provided by:
Italian College of General Practitioners and Primary Care
Text and Data Mining valid from 2019-03-09
First Online: 9 March 2019
Compliance with Ethical Standards
: This work was supported by the Italian College of General Practitioners and Primary Care, who played no role in the study design, execution, analysis or interpretation of data, writing of the paper, or decision to submit the paper for publication.
: Francesco Lapi provided consultancies in protocol preparation for epidemiological studies and data analyses for IBSA and Angelini. Claudio Cricelli provided clinical consultancies for IBSA, Angelini, Grunenthal, Alfa Wasserman, Pfizer, Prostrakan, Molteni, Dompè and Teva. Alberto Magni provided clinical consultancies for Bayer, Angelini, Doc and AlfaSigma. Niccolò Lombardi, Alfredo Vannacci, Alessandra Bettiol, Ettore Marconi, Serena Pecchioli, have no conflict of interest to disclose.
: With regard to the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), the present study does not require approval by an Ethics Committee in Italy (Italian Drug Agency note dated 3 August 2007).